MCAM and melanoma: In a more advanced study the effect of ABX-IL-8 in combination with an antibody against a melanoma cell adhesion protein, MUC18, and dacarbazine, the gold standard anti-melanoma drug, is suggested as a novel treatment that could overcome metastatic melanoma resistance to chemotherapy and improve survival of patients [194].